Links among paroxetine-induced sexual dysfunctions, gender, and CYP2D6 activity

Journal of Sex and Marital Therapy

Volumn 33, Issue 4, 2007, Pages 343-355

  Žourková, Alexandra ^a   Češková, Eva ^a   Hadašová, Eva ^a   Ravčuková, Barbara ^a  

^a MASARYK UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2D6; PAROXETINE;

ADULT; ANXIETY DISORDER; ARIZONA SEXUAL EXPERIENCE SCALE; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; ENZYME ACTIVITY; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLISM; PHENOTYPE; RATING SCALE; SEXUAL DYSFUNCTION; STATISTICAL SIGNIFICANCE;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CYTOCHROME P-450 CYP2D6; CZECH REPUBLIC; DEPRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LIBIDO; MALE; MIDDLE AGED; PAROXETINE; PHENOTYPE; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL; TREATMENT OUTCOME;

EID: 34249889916     PISSN: 0092623X     EISSN: 15210715     Source Type: Journal    
DOI: 10.1080/00926230701385589     Document Type: Article

References (43)

1. Agundéz J. A. G., Ledsdma M. C., Lafeto J. M., & Benitez J. (1995). Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population. Clinical Pharmacology and Therapeutics, 57, 265-269.
2. Baldessarini, R. J., & Marsch, E. (1990). Fluoxetine and side effects. Archives of General Psychiatry, 47, 191-192.
3. Baldwin, R. C. (2000). Prognosis of depression. Current Opinion in Psychiatry, 13, 81-85.
4. Bock, K. W., Schrenk, D., Foerster, A., Griese, E. U., Morike, K., Brockmeier, D., & Eichelbaum, M. (1994). The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronyltransferases in man using sparteine, caffeine, and paracetamol as probes. Pharmacogenetics, 4, 209-218.
5. Brosen, K., Hansen, J. G., Nielsen, K. K., Sindrup, S. H., & Gram, L. F. (1993). Inhibition by paroxetine or dsipramine metabolism in extensive but not in poor metabolisers of sparteine. European Journal of Clinical Pharmacology, 44, 349-355.
6. Dalén, P., Dahl, M. L., Ruiz, M. L., Nordin, J., & Bertilsson, L. (1998). 10-Hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes. Clinical Pharmacology and Therapeutics, 63, 444-452.
7. Gregorian, R. S., Golden, K. A., Bahce, A., Goodman, C., Kwong, W. J., & Khan, Z. M. (2002). Anti-depressant-induced sexual dysfunction. Annals of Pharmacotherapy, 3, 1577-1589.
8. Guy, W. (1976). ECDU assessment manual for psychopharmacology. U. S. Department of Health, Education and Welfare publication (ADM), 76-338. Rockville, MD: National Institute of Mental Health, 218-222.
9. Hadašová, E., Franke, G., Zschiesche, M., Češková, E., Zelenková, O., & Sigmund, W. (1996). Debrisoquine 4-hydroxylation and sulphamethazine N-acetylation in patients with schizophrenia and major depression. British Journal of Clinical Pharmacology, 41, 428-431.
10. Hagg, S., Spigset, O., & Dahlqvist, R. (2001). Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers. British Journal of Clinical Pharmacology, 51, 169-173.
11. Heim, M., & Meyer, U. A. (1990). Genotyping of poor metabolizers of debrisoquine by Allene-specific PCR amplification. Lancet, 336, 529-532.
12. Hensley, P. P., & Nurnberg, H. G. (2002). SSRI sexual dysfunction: A female perspective. Journal of Sex & Marital Therapy, 28, 143-153.
13. Kalow, W., & Tyndale, R. F. (1992). Debrisoquine/sparteine monooxygenase and other P450s in brain. In Pharmacogenetics of Drug Metabolism, W. Kalow (Ed.). New York: Pergamon Press, 649-656.
14. Kohler, D., Hartter, S., Fuchs, S., Sieghart, W., & Hiemke, C. (1997). CYP2D6 genotype and phenotyping by determination of dextromethorphan and metabolites in serum of healthy controls and of patients under psychotropic medication. Pharmacogenetics, 6, 453-461.
15. Lane, R. M. (1997). A critical review of SSRI-related sexual dysfunction, incidence, possible aetiology and implications for management. Journal of Psychopharmacology, 11, 72-82.
16. Lin, K., & Poland, R. E. (1995). Ethnicity, culture, psychopharmacology. In Psychopharmacology: The fourth generation of progress, F. E. Bloom & D. J. Kupfer (Eds.). New York: Raven Press, 1907-1917.
17. Llerena, A., Edeman, G., Cobaleda, J., Benitez, J., Schalling, D., & Bertilsson, L. (1993). Relationship between personality and debrisoquine hydroxylation capacity. Acta Psychiatrica Scandinavica, 87, 23-28.
18. Loscher, W., & Potschka, H. (2005). Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. Journal of the American Society for Experimental NeuroTherapeutics, 2, 86-98.
19. McCune, J. S., Lindley, C., Decker, J. L., Williamson, K. M., Meadowcroft, A. M., Graff, D., Sawyer, W. T., Blough, D. K., & Pieper, J. A. (2001). Lack of gender differences and large intrasubject variability in cytochrome P450 activity measured by phenotyping with dextromethorphan. Journal of Clinical Pharmacology, 41, 723-731.
20. McGahuey, C. A., Delgado, P. L., & Gelenberg, A. J. (1999). Assessment of sexual dysfunction using the Arizona sexual experiences scale (ASEX) and implications for the treatment of depression. Psychiatric Annals, 29, 39-45.
21. Merino, M. J., Gonzales, P., Muniz, J., & Bobes, J. (2000). Sexual dysfunction in depressed patients undergoing treatment with anti-depressants. International Journal of Psychiatry in Clinical Practice, 4, 311-317.
22. Montejo-Gonzales, A. L., Liorca, G., Izquierdo, J. A., Ledesma, A., Bousono, M., Calcedo, A., Carrasco, J. L., Ciudad, J., Daniel, E., De la Gandara, J., Derecho, J., Franco, M., Gomez, M. J., Macias, J. A., Martin, T., Perez, V., Sanchez, J. M., Sanchez, S., & Vicens, E. (1997). SSRI-induced sexual dysfunction: Fluoxetine, paroxetine, sertraline and fluvoxamine in a prospective, multicenter and descriptive clinical study of 344 patients. Journal of Sex & Marital Therapy, 23, 176-194.
23. Murphy, G. M., Kremer, C., Rodriguez, H. E., & Schatzberg, A. F. (2003). Pharmacogenetics of anti-depressant medication intolerance. American Journal of Psychiatry, 160, 1830-1835.
24. Niznik, H. B., Tyndale, R. F., & Sallee, R. F. (1990). The dopamine transporter and cytochrome P450IID1 (debrisoquine 4-hydroxylase) in brain, resolution and identification of two distinct GBR-12935 proteins. Archives of Biochemistry and Biophysics, 276, 424-432.
25. Parker, G., Parker, K., Austin, M. P., Mitchell, P., & Brotchie, H. (2003). Gender differences in response to differing anti-depressant drug classes: Two negative studies. Psychological Medicine, 33, 1473-1477.
26. Payami, H., Zhu, M., Montimurro, J., Keefe, R., McCulloh, C. C., & Mores, L. (2005). One step closer to fixing association studies: Evidence for age- and gender-specific allele frequency variations and deviations from Hardy-Weinberg expectations in controls. Human Genetics, 118, 322-330.
27. Piazza, L. A., Markowitz, J. C., Kocsis, J. H., Leon, A. C., Portera, L., Miller, N. L., & Adler, D. (1997). Sexual functioning in chronically depressed patients treated with SSRI anti-depressants: A pilot study. American Journal of Psychiatry, 154, 1757-1759.
28. Preskorn, S. H., & Magnus, R. D. (1994). Inhibition of hepatic P 450 isoenzymes by serotonin selective reuptake inhibitors: In vitro and in vivo findings and their implications for patient care. Psychopharmacology Bulletin, 30, 251-259.
29. Rau, T., Wohlleben, G., Wurme, H., Thuerauf, N., Lunkenheimer, J., Lanczik, M., & Esche, K. (2004). CYP2D6 genotype: Impact on averse effects and nonresponse during treatment with anti-depressants - A pilot study, Clinical Pharmacology and Therapeutics, 75, 386-393.
30. Segraves, R. T. (1989). Effects of psychotropic drugs on human erection and ejaculation. Archives of General Psychiatry, 46, 275-284.
31. Segraves, R. T., & Balon, R. (2003). Sexual pharmacology: Fast facts. New York: Norton & Company Inc.
32. Shen, W.W., & Hsu, J. H. (1995). Female sexual side effects associated with selective serotonin reuptake inhibitors: A descriptive clinical study of 33 patients. International Journal of Psychiatry in Medicine, 25, 239-248.
33. Sindrup, S. H., Brosen, K., Gram, L. F., Hallas, J., Skjelbo, E., Allen, A., Allen, G. D., Cooper, S. M., Mellows, G., & Tasker, T. C. (1992). The relationship between paroxetine and the sparteine oxidation polymorphism. Clinical Pharmacology and Therapeutics, 51, 278-287.
34. Spina, E., Gitto, C., Avenoso, A., Campo, G. M., Caputti, A. P., & Peucca, E. (1997). Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: a prospective study. European Journal of Clinical Pharmacology, 51, 395-398.
35. Statistica CZ. (2001). StatSoft CR, Inc. Statistica CZ, version 6. Prague, Czech Republic: Statistica CZ.
36. Tanaka, E. (1999). Gender-related differences in pharmacokinetics and their clinical significance. Journal of Clinical Pharmacy and Therapeutics, 24, 339-346.
37. Thase, M. E. (1999). Long-term nature of depression. Journal of Clinical Psychiatry, 60 (suppl.14), 3-9.
38. Tucker, G. (2004). Pharmacogenetics-expectations and reality (Editorial). British Medical Journal, 329, 4-6.
39. Tyndale, R. F., Sunahara, R., & Inaba, T. (1991). Neuronal cytochrome P450IIID1 (debrisoquine/sparteine-type): Potent inhibition of activity by (-)-cocaine and nucleotide sequence identity to human hepatic P450 gene CYP2D6. Molecular Pharmacology, 40, 63-68.
40. World Health Organization. (1992). International classification of mental and behavioural disorders. Geneva: Authors.
41. Zanger, U. M., Klein, K., Richter, T., Toscano, C., & Zukunft, J. (2005). Impact of genetic polymorphism in relation to other factors on expression and function of human drug-metabolizing P450s. Toxicology Mechanism and Methods, 15, 121-124.
42. Žourková, A., & Hadašová, E. (2002). Relationship between CYP2D6 metabolic status and sexual dysfunction in paroxetine treatment. Journal of Sex & Marital Therapy, 28, 451-461.
43. Žourková, A., & Novotná, J. (2006). Gender differences as to efficacy and sexual functions in the long-term trazodone treatment (preliminary results). International Journal of Psychiatry in Clinical Practice, 10, 154-159.